Literature DB >> 9758295

Cerebrospinal fluid magnesium level as a prognostic factor in ischaemic stroke.

Y Lampl1, D Geva, R Gilad, Y Eshel, L Ronen, I Sarova-Pinhas.   

Abstract

Magnesium has been reported to have a dilatatory effect on cerebral arteries. Reduction of extracellular Mg+2 has been shown to be directly correlated with the intensity of cerebral spasm. A neuroprotective effect of magnesium in stroke has also been hypothesized. The aim of our study was to examine the Mg+2 levels in serum and cerebrospinal fluid (CSF) in the early stage of stroke and to evaluate the correlation between Mg+2 levels and the development of neurological deficits. Between 1986 and 1994, 96 patients who had a stroke of 24- to 48-h duration were enrolled in the study. Serum and CSF levels of magnesium were checked on admission, 2448 h after the onset of stroke. Using a neurological score, the neurological deficit was assessed on the 1st day, 1 and 4 weeks later. Computed tomography (CT) was performed after 1 week, and the volume and location of infarction were calculated and measured. Statistical analysis was performed for cortical and subcortical patients separately, using Spearman correlation and multiple linear and logistic regression analyses. Significant correlation was found between CSF Mg+2 and the size of the infarct (P < 0.0001). There was no correlation between serum Mg+2 and CSF Mg+2 levels. Regression analysis demonstrated an increase in the values of the Mathew Neurological Score with higher CSF Mg+2 levels. This association remained true after other factors such as age, associated heart disease, diabetes and infarction size had been taken into account by the regression model. The results confirm that there is a relationship between a low Mg+2 concentration in CSF during the first 48 h after onset of ischaemic stroke and the intensity of the neurological deficit. The therapeutic consequence of this finding may have some importance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9758295     DOI: 10.1007/s004150050249

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  5 in total

Review 1.  Magnesium neuroprotection is limited in humans with acute brain injury.

Authors:  J Andrew McKee; Randall P Brewer; Gary E Macy; Cecil O Borel; James D Reynolds; David S Warner
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Detection of metals and metalloproteins in the plasma of stroke patients by mass spectrometry methods.

Authors:  Phanichand Kodali; Karnakar R Chitta; Julio A Landero Figueroa; Joseph A Caruso; Opeolu Adeoye
Journal:  Metallomics       Date:  2012-09-14       Impact factor: 4.526

3.  A preliminary study of metalloproteins in CSF by CapLC-ICPMS and NanoLC-CHIP/ITMS.

Authors:  Jenny Ellis; Estela Del Castillo; Maria Montes Bayon; Rudolf Grimm; Joseph F Clark; Gail Pyne-Geithman; Steve Wilbur; Joseph A Caruso
Journal:  J Proteome Res       Date:  2008-07-29       Impact factor: 4.466

4.  Investigating dynamic structural and mechanical changes of neuroblastoma cells associated with glutamate-mediated neurodegeneration.

Authors:  Yuqiang Fang; Catherine Y Y Iu; Cathy N P Lui; Yukai Zou; Carmen K M Fung; Hung Wing Li; Ning Xi; Ken K L Yung; King W C Lai
Journal:  Sci Rep       Date:  2014-11-17       Impact factor: 4.379

5.  Magnesium sulfate protects against the bioenergetic consequences of chronic glutamate receptor stimulation.

Authors:  Pascaline Clerc; Christina A Young; Evan A Bordt; Alina M Grigore; Gary Fiskum; Brian M Polster
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.